NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.10 +0.01 (+0.07 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$14.10
Today's Range$14.01 - $14.34
52-Week Range$11.47 - $17.99
Volume746,873 shs
Average Volume983,687 shs
Market Capitalization$1.47 billion
P/E Ratio12.05
Dividend YieldN/A
Beta2.12

About Innoviva (NASDAQ:INVA)

Innoviva logoInnoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INVA
CUSIP88338T10
Phone650-238-9600

Debt

Debt-to-Equity Ratio-2.28
Current Ratio27.89
Quick Ratio27.89

Price-To-Earnings

Trailing P/E Ratio12.05
Forward P/E Ratio6.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$217.22 million
Price / Sales6.61
Cash Flow$1.4611 per share
Price / Cash9.65
Book Value($2.09) per share
Price / Book-6.75

Profitability

EPS (Most Recent Fiscal Year)$1.17
Net Income$134.14 million
Net Margins64.11%
Return on Equity-63.57%
Return on Assets44.05%

Miscellaneous

Employees12
Outstanding Shares101,820,000

Innoviva (NASDAQ:INVA) Frequently Asked Questions

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva (NASDAQ:INVA) issued its quarterly earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.50 by $0.23. The biotechnology company had revenue of $52.40 million for the quarter, compared to analyst estimates of $71.84 million. Innoviva had a negative return on equity of 63.57% and a net margin of 64.11%. The business's revenue for the quarter was up 29.4% on a year-over-year basis. During the same period last year, the company posted $0.19 EPS. View Innoviva's Earnings History.

When is Innoviva's next earnings date?

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

What price target have analysts set for INVA?

6 analysts have issued 12 month price objectives for Innoviva's stock. Their forecasts range from $8.00 to $16.00. On average, they expect Innoviva's stock price to reach $13.20 in the next year. View Analyst Ratings for Innoviva.

Are investors shorting Innoviva?

Innoviva saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 11,842,171 shares, a decrease of 11.3% from the April 13th total of 13,344,078 shares. Based on an average daily trading volume, of 1,262,701 shares, the short-interest ratio is presently 9.4 days. Approximately 17.7% of the company's shares are sold short.

Who are some of Innoviva's key competitors?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:
  • Mr. Eric d'Esparbes, Interim Principal Exec. Officer, Sr. VP & CFO (Age 50)
  • Dr. Theodore J. Witek Jr., Sr. VP & Chief Scientific Officer (Age 60)
  • Mr. George B. Abercrombie M.B.A., R.Ph., RPh, MBA, Sr. VP & Chief Commercial Officer (Age 63)
  • Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
  • Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

Has Innoviva been receiving favorable news coverage?

Headlines about INVA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innoviva earned a media sentiment score of 0.23 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.68%), Dimensional Fund Advisors LP (1.69%), First Eagle Investment Management LLC (1.34%), Northern Trust Corp (1.01%), UBS Group AG (0.70%) and Victory Capital Management Inc. (0.63%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., JPMorgan Chase & Co., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Smith Asset Management Group LP, Systematic Financial Management LP, Camarda Financial Advisors LLC and Northern Trust Corp. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.

Which institutional investors are buying Innoviva stock?

INVA stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, PNC Financial Services Group Inc., WINTON GROUP Ltd, Millennium Management LLC, Hsbc Holdings PLC, Algert Global LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for Innoviva.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $14.10.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.47 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

How can I contact Innoviva?

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]


MarketBeat Community Rating for Innoviva (INVA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Innoviva (NASDAQ:INVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Innoviva in the last 12 months. Their average twelve-month price target is $13.20, suggesting that the stock has a possible downside of 6.38%. The high price target for INVA is $16.00 and the low price target for INVA is $8.00. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.172.172.002.00
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.20$13.40$13.40$13.00
Price Target Upside: 6.38% downside17.13% downside8.59% downside0.46% downside

Innoviva (NASDAQ:INVA) Consensus Price Target History

Price Target History for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2018Stifel NicolausLower Price TargetHold ➝ Hold$17.00 ➝ $16.00MediumView Rating Details
4/19/2018Berenberg BankInitiated CoverageBuyLowView Rating Details
11/20/2017Deutsche BankInitiated CoverageHold$13.00N/AView Rating Details
10/24/2017Robert W. BairdReiterated RatingHold$13.00N/AView Rating Details
10/23/2017CowenSet Price TargetBuy$16.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingUnderweight$7.00 ➝ $8.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Innoviva (NASDAQ:INVA) Earnings History and Estimates Chart

Earnings by Quarter for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA) Earnings Estimates

Current Year EPS Consensus Estimate: $2.09 EPS
Next Year EPS Consensus Estimate: $2.68 EPS

Innoviva (NASDAQ INVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018$0.54N/AView Earnings Details
4/26/2018Q1 2018$0.50$0.27$71.84 million$52.40 millionViewN/AView Earnings Details
2/8/2018Q4 2017$0.49$0.50$67.41 million$69.52 millionViewListenView Earnings Details
10/25/2017Q3 2017$0.34$0.21$57.18 million$48.64 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.28$0.30$50.53 million$58.60 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.27$0.15$47.66 million$40.50 millionViewN/AView Earnings Details
2/9/2017Q4 2016$0.19$0.22$40.72 million$43.60 millionViewListenView Earnings Details
10/27/2016Q316$0.19$0.16$38.71 million$33.30 millionViewListenView Earnings Details
7/28/2016Q216$0.12$0.17$31.13 million$32.47 millionViewListenView Earnings Details
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details
7/29/2015Q2($0.0630)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details
5/6/2015Q115($0.08)($0.09)$8.64 million$6.90 millionViewListenView Earnings Details
2/18/2015Q414($0.14)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details
10/30/2014Q314($0.15)($0.19)$5.06 million$1.00 millionViewN/AView Earnings Details
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details
8/6/2014Q214($0.53)($0.18)$4.39 million$0.93 millionViewN/AView Earnings Details
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details
4/26/2012$1.02$0.93ViewN/AView Earnings Details
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.28)($0.28)ViewN/AView Earnings Details
2/15/2011Q4 2010($0.28)($0.25)ViewN/AView Earnings Details
10/21/2010Q3 2010($0.27)($0.29)ViewN/AView Earnings Details
7/22/2010Q2 2010($0.27)($0.28)ViewN/AView Earnings Details
4/21/2010Q1 2010($0.28)($0.35)ViewN/AView Earnings Details
2/11/2010Q4 2009($0.34)($0.35)ViewN/AView Earnings Details
10/27/2009Q3 2009($0.34)($0.35)ViewN/AView Earnings Details
7/23/2009Q2 2009($0.33)($0.35)ViewN/AView Earnings Details
4/22/2009Q1 2009($0.29)($0.29)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.36)($0.26)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.35)($0.34)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.48)($0.36)ViewN/AView Earnings Details
4/21/2008Q1 2008($0.47)($0.49)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.56)($0.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Innoviva (NASDAQ:INVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2015quarterly$0.257.01%9/8/20159/10/20159/30/2015
5/7/2015quarterly$0.256.43%6/10/20156/12/20156/30/2015
2/24/2015quarterly$0.255.85%3/10/20153/12/20153/31/2015
10/31/2014quarterly$0.256.24%11/21/201411/25/201412/23/2014
8/6/2014quarterly$0.258/26/20148/28/20149/18/2014
(Data available from 1/1/2013 forward)

Insider Trades

Innoviva (NASDAQ INVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.44%
Institutional Ownership Percentage: 74.49%
Insider Trading History for Innoviva (NASDAQ:INVA)
Insider Trading History for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ INVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2018Eric DesparbesCFOSell5,808$14.40$83,635.20376,965View SEC Filing  
5/21/2018George B AbercrombieVPSell8,000$14.40$115,200.00305,235View SEC Filing  
2/21/2018Eric DesparbesInsiderSell5,378$16.52$88,844.56View SEC Filing  
2/21/2018George B AbercrombieVPSell8,000$16.51$132,080.00View SEC Filing  
12/4/2017Michael W AguiarInsiderSell12,022$13.13$157,848.86980,907View SEC Filing  
11/21/2017Eric DesparbesCFOSell15,285$13.28$202,984.80337,027View SEC Filing  
11/21/2017George B AbercrombieVPSell5,215$13.26$69,150.90263,866View SEC Filing  
8/21/2017Eric DesparbesCFOSell1,825$12.20$22,265.00344,993View SEC Filing  
5/22/2017Eric DesparbesCFOSell1,825$11.85$21,626.25352,588View SEC Filing  
5/22/2017Theodore J Jr. WitekVPSell7,815$12.01$93,858.15251,968View SEC Filing  
2/21/2017Eric DesparbesCFOSell1,825$12.07$22,027.75356,121View SEC Filing  
11/22/2016Theodore L Witek JrVPSell3,700$10.84$40,108.00157,131View SEC Filing  
11/21/2016Eric DesparbesCFOSell1,800$10.89$19,602.00View SEC Filing  
8/22/2016Eric DesparbesCFOSell3,700$11.77$43,549.00239,893View SEC Filing  
5/18/2016James L TyreeDirectorSell813$10.47$8,512.1150,697View SEC Filing  
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59690,106View SEC Filing  
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Innoviva (NASDAQ INVA) News Headlines

Source:
DateHeadline
BRIEF-Innoviva Names Geoffrey Hulme As Interim Principal Executive OfficerBRIEF-Innoviva Names Geoffrey Hulme As Interim Principal Executive Officer
www.reuters.com - May 23 at 9:12 AM
Insider Selling: Innoviva (INVA) CFO Sells 5,808 Shares of StockInsider Selling: Innoviva (INVA) CFO Sells 5,808 Shares of Stock
www.americanbankingnews.com - May 22 at 10:28 PM
George B. Abercrombie Sells 8,000 Shares of Innoviva (INVA) StockGeorge B. Abercrombie Sells 8,000 Shares of Innoviva (INVA) Stock
www.americanbankingnews.com - May 22 at 10:28 PM
Innoviva (INVA) Names Geoffrey Hulme as Interim Principal Executive OfficerInnoviva (INVA) Names Geoffrey Hulme as Interim Principal Executive Officer
www.streetinsider.com - May 22 at 4:24 PM
Innoviva Names Geoffrey Hulme as Interim Principal Executive OfficerInnoviva Names Geoffrey Hulme as Interim Principal Executive Officer
finance.yahoo.com - May 22 at 4:24 PM
Stock Traders Buy Large Volume of Innoviva Call Options (INVA)Stock Traders Buy Large Volume of Innoviva Call Options (INVA)
www.americanbankingnews.com - May 22 at 6:54 AM
Innoviva (INVA) Receives Consensus Rating of "Hold" from AnalystsInnoviva (INVA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 19 at 1:35 AM
$73.95 Million in Sales Expected for Innoviva (INVA) This Quarter$73.95 Million in Sales Expected for Innoviva (INVA) This Quarter
www.americanbankingnews.com - May 13 at 4:14 AM
Innoviva (INVA) Short Interest UpdateInnoviva (INVA) Short Interest Update
www.americanbankingnews.com - May 13 at 1:40 AM
GlaxoSmithKlines Trelegy Ellipta (fluticasone furoate + vilanterol + umeclidinium bromide) Drug Overview Report 2018 ...GlaxoSmithKline's Trelegy Ellipta (fluticasone furoate + vilanterol + umeclidinium bromide) Drug Overview Report 2018 ...
www.businesswire.com - May 11 at 4:29 PM
$0.62 EPS Expected for Innoviva (INVA) This Quarter$0.62 EPS Expected for Innoviva (INVA) This Quarter
www.americanbankingnews.com - May 11 at 3:25 PM
Blog Exposure - INSYS Commences Phase-2 Clinical Trial of Cannabidiol Oral Solution for Treatment of Prader-Willi SyndromeBlog Exposure - INSYS Commences Phase-2 Clinical Trial of Cannabidiol Oral Solution for Treatment of Prader-Willi Syndrome
finance.yahoo.com - May 1 at 9:29 AM
Innoviva (INVA) Downgraded by Zacks Investment ResearchInnoviva (INVA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 7:52 AM
Innoviva (INVA) Rating Lowered to Hold at BidaskClubInnoviva (INVA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 28 at 7:40 AM
Innoviva (INVA) Rating Increased to Buy at Zacks Investment ResearchInnoviva (INVA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 27 at 1:59 PM
Innoviva (INVA) Price Target Cut to $16.00Innoviva (INVA) Price Target Cut to $16.00
www.americanbankingnews.com - April 27 at 11:21 AM
Innoviva (INVA) Posts Quarterly  Earnings Results, Misses Expectations By $0.15 EPSInnoviva (INVA) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS
www.americanbankingnews.com - April 26 at 11:32 PM
BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35
www.reuters.com - April 26 at 9:16 AM
Innoviva: 1Q Earnings SnapshotInnoviva: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 9:16 AM
Innoviva Reports First Quarter 2018 Financial ResultsInnoviva Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 26 at 9:16 AM
$76.03 Million in Sales Expected for Innoviva (INVA) This Quarter$76.03 Million in Sales Expected for Innoviva (INVA) This Quarter
www.americanbankingnews.com - April 26 at 6:10 AM
Innoviva (INVA) Downgraded to Hold at Zacks Investment ResearchInnoviva (INVA) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 11:36 AM
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPDOnce-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD
finance.yahoo.com - April 24 at 4:40 PM
Innoviva (INVA) Receives Average Recommendation of "Hold" from AnalystsInnoviva (INVA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 24 at 1:30 AM
$0.57 EPS Expected for Innoviva (INVA) This Quarter$0.57 EPS Expected for Innoviva (INVA) This Quarter
www.americanbankingnews.com - April 24 at 1:14 AM
Innoviva (INVA) Research Coverage Started at Berenberg BankInnoviva (INVA) Research Coverage Started at Berenberg Bank
www.americanbankingnews.com - April 19 at 11:46 AM
Innoviva (INVA) & GlaxoSmithKline plc (GSK) Highlight NEJM Publication of Landmark IMPACT Study Showing ...Innoviva (INVA) & GlaxoSmithKline plc (GSK) Highlight NEJM Publication of Landmark IMPACT Study Showing ...
www.streetinsider.com - April 19 at 9:29 AM
Innoviva (INVA) Lowered to "Buy" at BidaskClubInnoviva (INVA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 18 at 10:06 AM
Innoviva (INVA) Scheduled to Post Earnings on WednesdayInnoviva (INVA) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:28 AM
Adjusted Price Targets For This Bio-Pharmaceutical Holding Company: More Than 20% UpsideAdjusted Price Targets For This Bio-Pharmaceutical Holding Company: More Than 20% Upside
seekingalpha.com - April 17 at 4:51 PM
Innoviva (INVA) Upgraded by Zacks Investment Research to "Buy"Innoviva (INVA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 17 at 11:04 AM
Innoviva (INVA) Stock Rating Reaffirmed by Stifel NicolausInnoviva (INVA) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - April 15 at 10:58 AM
Cowen Reiterates $16.00 Price Target for Innoviva (INVA)Cowen Reiterates $16.00 Price Target for Innoviva (INVA)
www.americanbankingnews.com - April 15 at 9:31 AM
Innoviva (INVA) Upgraded to "Strong-Buy" at Zacks Investment ResearchInnoviva (INVA) Upgraded to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - April 14 at 8:35 PM
Innoviva Inc.: Buy This Small-Cap Biopharma Royalty Holding Company With 50% UpsideInnoviva Inc.: Buy This Small-Cap Biopharma Royalty Holding Company With 50% Upside
seekingalpha.com - April 10 at 4:27 PM
Innoviva Inc (INVA) Expected to Post Quarterly Sales of $73.83 MillionInnoviva Inc (INVA) Expected to Post Quarterly Sales of $73.83 Million
www.americanbankingnews.com - April 9 at 4:28 AM
Innoviva (INVA) Rating Increased to Buy at ValuEngineInnoviva (INVA) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 8 at 11:49 AM
Innoviva Inc (INVA) Expected to Post Earnings of $0.53 Per ShareInnoviva Inc (INVA) Expected to Post Earnings of $0.53 Per Share
www.americanbankingnews.com - April 7 at 1:10 AM
Innoviva (INVA) Lowered to "Hold" at Zacks Investment ResearchInnoviva (INVA) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:02 AM
Innoviva Target of Unusually Large Options Trading (INVA)Innoviva Target of Unusually Large Options Trading (INVA)
www.americanbankingnews.com - April 3 at 7:35 AM
Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar ElliptaBiotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta
finance.yahoo.com - April 2 at 4:29 PM
Innoviva Inc (INVA) Given Consensus Rating of "Hold" by AnalystsInnoviva Inc (INVA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 30 at 1:32 AM
Breo Ellipta (GlaxoSmithKline/Innoviva) Drug Analysis 2018 - ResearchAndMarkets.comBreo Ellipta (GlaxoSmithKline/Innoviva) Drug Analysis 2018 - ResearchAndMarkets.com
www.businesswire.com - March 29 at 4:27 PM
March Growth Stock OpportunitiesMarch Growth Stock Opportunities
finance.yahoo.com - March 28 at 4:24 PM
Zacks Investment Research Downgrades Innoviva (INVA) to SellZacks Investment Research Downgrades Innoviva (INVA) to Sell
www.americanbankingnews.com - March 25 at 11:01 AM
BidaskClub Upgrades Innoviva (INVA) to "Strong-Buy"BidaskClub Upgrades Innoviva (INVA) to "Strong-Buy"
www.americanbankingnews.com - March 24 at 6:13 PM
Zacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Quarterly Sales of $73.83 MillionZacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Quarterly Sales of $73.83 Million
www.americanbankingnews.com - March 23 at 7:56 AM
Innoviva (INVA) Upgraded to Buy by ValuEngineInnoviva (INVA) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - March 18 at 10:28 PM
Innoviva (INVA) versus Teligent (TLGT) Head-To-Head ContrastInnoviva (INVA) versus Teligent (TLGT) Head-To-Head Contrast
www.americanbankingnews.com - March 15 at 3:46 PM
Have Investors Priced In Innoviva Inc’s (NASDAQ:INVA) Growth?Have Investors Priced In Innoviva Inc’s (NASDAQ:INVA) Growth?
finance.yahoo.com - March 10 at 9:40 AM

SEC Filings

Innoviva (NASDAQ:INVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Innoviva (NASDAQ:INVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Innoviva (NASDAQ INVA) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.